Today we will discuss possible differences men and women may have in health-related quality of life, symptom management, treatment management, and even personality.
Compliance and Disease Management
A recent study published in the Journal of Managed Care Pharmacy (JMCP) sought to evaluate gender differences in self-reported clinical characteristics, symptom awareness, and perceived ability to manage therapy among MS patients taking a disease-modifying drug. How do we respond differently to our MS?
Of 4700 patients surveyed, only 44.1% responded. Of those 2022 patients, 80.6% were female, 82.3% were relapsing-remitting, and 83.1% were taking Avonex (33.4%), Rebif (15.9%), or Copaxone (33.8%). Curious that Betaseron, Tysabri, or Novantrone were not called out as well, only referred to as the 16.9% who were not using one of the drugs mentioned above.
The flip side of the 2022 patients who responded is that 19.4% were male (4:1 ratio, women to men) and 17.7% were progressive. Comparatively, the men were typically older and a great proportion of them had more progressive MS. This reinforces what we discussed in MS in Men vs. Women: Does Gender Matter?
Read this post in its entirety:
MS in Men and Women: Disability, Compliance, Personality, and Mental Health